Dr Thibault Griseri, PhD

Profile

I completed a PhD in Immunology in France working on NKT cells and type 1 diabetes in Dr. Agnès Lehuen’s group in Paris. I moved to the University of Oxford in 2007 to work as a postdoctoral researcher in Prof. Fiona Powrie's laboratory, investigating the regulation of immune responses in inflammatory bowel disease (IBD), with a special focus on Foxp3+ regulatory T cells and granulocytes (neutrophils and eosinophils).

In 2013, I joined the Kennedy Institute of Rheumatology to work on chronic inflammatory arthritis with Prof Sir Marc Feldmann, and subsequently obtained a Career Development Fellowship funded by Arthritis Research UK (now Versus Arthritis) and the Kennedy Trust for Rheumatology Research. During that time, I developed a research programme investigating the impact of inflammatory cytokines on haematopoiesis, and the contribution of haematopoietic stem cells and progenitor cells to the chronicity and severity of intestinal and joint inflammation, in the context of spondyloarthritis. 

In 2021, I joined Queen Mary University of London and the Blizard Institute as a Lecturer in Immunology, to contribute to immunology teaching, and pursue my research on the regulation of haematopoiesis and myeloid cell responses during chronic inflammatory diseases of the intestine and of the joints. 

Teaching

Lecturer in Immunology in the Nanchang University Joint Programme (Basic Immunology)

Problem Based Learning (tutor) for undergraduate medical students – MBBS

Research

Research Interests:

By bringing together the fields of Immunology and Haematology, I am investigating the regulation of haematopoiesis during dysregulated immune responses to identify novel therapeutic targets, with a special focus on chronic inflammatory diseases affecting the intestine and the joints.

My research goal is to understand how immune cells and inflammatory signals (e.g. cytokines and chemokines) influence the homeostasis of haematopoietic stem cells and their differentiation into haematopoietic progenitors (myeloid, lymphoid, erythroid lineages), using preclinical models of chronic inflammatory diseases and clinical samples. Importantly, recent studies showed that these stem cells and progenitors, which are located in the bone marrow but also at extramedullary sites (spleen, liver and target organs) under pathogenic conditions, are more reactive to environmental cues than previously anticipated, for example to TLR stimuli, IFNs, IL-1 and TNF.

I am especially interested in the regulation of myelopoiesis and innate cell responses, as granulocytes (e.g. neutrophils and eosinophils) and inflammatory monocytes/macrophages can inflict irreversible tissue damage during chronic inflammatory diseases, for example to the intestine in inflammatory bowel disease, to the joints in rheumatoid arthritis or to both in spondyloarthritis.

Although my expertise lies in arthritis and intestinal inflammation, in future developments of my research I would also be interested in widening my study of myeloid cell and haematopoiesis regulation to other immune-mediated diseases and infectious diseases.

Publications

Key publications

Swann J, Koneva L, Regan-Komito D, Sansom S, Powrie F, and Griseri T. IL-33 promotes anemia of chronic inflammation by inhibiting differentiation of erythroid progenitors. Journal of Experimental Medicine. 2020 DOI: 10.1084/jem.20200164

Regan-Komito D, Swann J, Demetriou P, Cohen ES, Horwood, N, Sansom S, and Griseri T. GM-CSF drives dysregulated hematopoietic stem cell activity and pathogenic extramedullary myelopoiesis in experimental spondyloarthritis. Nature Communications. 2020 DOI: 10.1038/s41467-019-13853-4

Griseri T, Arnold IC, Pearson C, Krausgruber T, Schiering C, Franchini F, Schulthess J, McKenzie BS, Crocker PR, Powrie F. Granulocyte Macrophage Colony-Stimulating Factor-activated eosinophils promote Interleukin-23 driven chronic colitis. Immunity. 2015 DOI: 10.1016/j.immuni.2015.07.008

Griseri T, McKenzie BS, Schiering C, Powrie F. Dysregulated hematopoietic stem and pro-genitor cell activity promotes IL-23-driven chronic intestinal inflammation. Immunity. 2012 DOI: 10.1016/j.immuni.2012.08.025

Griseri T, Asquith M, Thompson C, Powrie F. OX40 is required for regulatory T cell-mediated control of colitis. Journal of Experimental Medicine. 2010 DOI: 10.1084/jem.20091618

All publications